A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P
The compound is supplied by NewBioRx as a lyophilized peptide to support long term stability and ease of storage
However, DPP-4 inhibitors have not reduced the risk of major adverse cardiovascular events, possibly because potentiation of SDF-1 enhances plaque growth and instability, activates deleterious neurohormonal mechanisms, and promotes cardiac inflammation and fibrosis
This limitation is exactly why adding Tesamorelin to the stack produces such dramatically different results for midsection appearance
Nature 565 , 312317 (2019)
This is due to an increase in activity of DDP-4, the enzyme responsible for inactivating GLP-1[5]